{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:19:59Z","timestamp":1775679599183,"version":"3.50.1"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014386","name":"Abbott Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bone.2018.06.011","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:22:33Z","timestamp":1529349753000},"page":"215-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Clinical utility of bone markers in various diseases"],"prefix":"10.1016","volume":"114","author":[{"given":"M.C.","family":"Vlot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"den Heijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.T.","family":"de Jongh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Vervloet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.F.","family":"Lems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Heijboer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2018.06.011_bb0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jbo.2015.01.002","article-title":"Use of urinary markers in cancer setting: a literature review","volume":"4","author":"Chiu","year":"2015","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bone.2018.06.011_bb0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bone.2018.06.011_bb0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jocd.2012.11.004","article-title":"Bone turnover markers in primary hyperparathyroidism","volume":"16","author":"Costa","year":"2013","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2018.06.011_bb0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","article-title":"Changing bone patterns with progression of chronic kidney disease","volume":"89","author":"Dr\u00fceke","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.maturitas.2011.07.021","article-title":"Primary hyperparathyroidism: skeletal and non-skeletal effects, diagnosis and management","volume":"70","author":"Pyram","year":"2011","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2018.06.011_bb0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1479-5876-11-201","article-title":"The clinical utility of bone marker measurements in osteoporosis","volume":"11","author":"Wheater","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12018-015-9185-x","article-title":"Bone turnover markers: a clinical review","volume":"13","author":"Gua\u00f1abens","year":"2015","journal-title":"Clin. Rev. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0040","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0045","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MED.0b013e3283591492","article-title":"Use of bone turnover markers in clinical practice","volume":"19","author":"Biver","year":"2012","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.bone.2018.06.011_bb0050","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrendo.2011.121","article-title":"Bone: reference bone turnover markers-just a fairy tale?","volume":"7","author":"Seibel","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bone.2018.06.011_bb0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0004563213515190","article-title":"Biochemical markers of bone turnover - uses and limitations","volume":"51","author":"Hlaing","year":"2014","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.bone.2018.06.011_bb0060","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","article-title":"A meta-analysis of reference markers of bone turnover for prediction of fracture","volume":"94","author":"Johansson","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3233\/BD-2010-0327","article-title":"Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?","volume":"33","author":"Lipton","year":"2011","journal-title":"Breast Dis."},{"key":"10.1016\/j.bone.2018.06.011_bb0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11914-011-0091-y","article-title":"Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy","volume":"10","author":"Schousboe","year":"2012","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0075","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.clinbiochem.2012.01.022","article-title":"The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis","volume":"45","author":"Szulc","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bone.2018.06.011_bb0080","first-page":"1700","article-title":"The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group","volume":"24","author":"Terpos","year":"2010","journal-title":"Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK"},{"key":"10.1016\/j.bone.2018.06.011_bb0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrrheum.2012.86","article-title":"Bone turnover markers: use in osteoporosis","volume":"8","author":"Naylor","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bone.2018.06.011_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3343\/alm.2012.32.2.105","article-title":"Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis","volume":"32","author":"Lee","year":"2012","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0095","first-page":"0","article-title":"Circulating markers of bone turnover","volume":"0","author":"Vervloet","year":"2017","journal-title":"J. Nephrol."},{"key":"10.1016\/j.bone.2018.06.011_bb0100","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00198-014-2646-0","article-title":"PINP as a biological response marker during teriparatide treatment for osteoporosis","volume":"25","author":"Krege","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0105","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/000456320003700402","article-title":"Measurement of osteocalcin","volume":"37","author":"Lee","year":"2000","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.bone.2018.06.011_bb0110","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2014-2910","article-title":"Paget's disease of bone: an endocrine society clinical practice guideline","volume":"99","author":"Singer","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAT.0000000000000092","article-title":"Towards optimising the provision of laboratory services for bone turnover markers","volume":"46","author":"Vasikaran","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.bone.2018.06.011_bb0120","first-page":"4695","article-title":"Paget's disease of bone: an osteoimmunological disorder?","volume":"9","author":"Numan","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bone.2018.06.011_bb0125","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1590\/0004-2730000002941","article-title":"Diagnosis and management of Paget's disease of bone","volume":"58","author":"Griz","year":"2014","journal-title":"Arq. Bras. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10067-010-1579-z","article-title":"Active Paget's disease of bone with normal biomarkers of bone metabolism: a case report and review of the literature","volume":"30","author":"Gkouva","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bone.2018.06.011_bb0135","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00198-015-3095-0","article-title":"Bone turnover markers in Paget's disease of the bone: a systematic review and meta-analysis","volume":"26","author":"Al Nofal","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bone.2010.09.002","article-title":"Bisphosphonates in Paget's disease","volume":"49","author":"Reid","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0145","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/jclinpath-2013-201688","article-title":"Paget's disease of bone: clinical review and update","volume":"66","author":"Bolland","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bone.2018.06.011_bb0150","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jcb.25291","article-title":"Biology and treatment of Paget's disease of bone","volume":"117","author":"Vallet","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bone.2018.06.011_bb0155","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMcp1204713","article-title":"Paget's disease of bone","volume":"368","author":"Ralston","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.clinbiochem.2012.03.023","article-title":"Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum","volume":"45","author":"Koivula","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bone.2018.06.011_bb0165","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.clinbiochem.2012.06.011","article-title":"Reprint: Paget's disease of bone \u2606","volume":"45","author":"Cundy","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bone.2018.06.011_bb0170","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1529-0131(199802)41:2<354::AID-ART20>3.0.CO;2-5","article-title":"Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease","volume":"41","author":"Garnero","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2018.06.011_bb0175","doi-asserted-by":"crossref","first-page":"E1740","DOI":"10.1210\/jc.2013-2264","article-title":"Traditional and novel bone remodeling markers in premenopausal and postmenopausal women","volume":"98","author":"Botella","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0180","first-page":"1","article-title":"Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups","volume":"18","author":"Burch","year":"2014","journal-title":"Health Technol. Assess. (Rockv)"},{"key":"10.1016\/j.bone.2018.06.011_bb0185","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0190","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1471-2474-12-167","article-title":"Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice","volume":"12","author":"D A","year":"2011","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bone.2018.06.011_bb0200","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.semarthrit.2011.01.005","article-title":"Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review","volume":"41","author":"Funck-Brentano","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bone.2018.06.011_bb0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jbspin.2011.05.004","article-title":"Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis","volume":"79","author":"Chopin","year":"2012","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.bone.2018.06.011_bb0210","first-page":"1","article-title":"Novel biological markers of bone: from bone metabolism to bone physiology","author":"Chapurlat","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.bone.2018.06.011_bb0220","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.06.011_bb0225","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11914-017-0353-4","article-title":"Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy","volume":"15","author":"Leder","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0230","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"8587","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2018.06.011_bb0235","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s00198-016-3573-z","article-title":"Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia","author":"Naylor","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0245","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1210\/jc.2012-2999","article-title":"Effects of 25-hydroxyvitamin D 3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate","volume":"97","author":"Olmos","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0250","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","author":"Eastell","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"issue":"7","key":"10.1016\/j.bone.2018.06.011_bb0255","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2018.06.011_bb0260","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.clinbiochem.2011.07.013","article-title":"Tumor-induced osteomalacia: the tumor may stay hidden!","volume":"44","author":"van der Rest","year":"2011","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bone.2018.06.011_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-09-0597","article-title":"Fibroblast growth factor 23 and its role in phosphate homeostasis","volume":"162","author":"Ramon","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2018.06.011_bb0270","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/0004563213510708","article-title":"Fibroblast growth factor 23","volume":"51","author":"Smith","year":"2014","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.bone.2018.06.011_bb0275","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2005.01.001","article-title":"Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET\/CT scan for the diagnosis and follow-up in one case","volume":"36","author":"Dupond","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0280","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa010839","article-title":"Octreotide therapy for tumor-induced osteomalacia","volume":"345","author":"Seufert","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0285","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11926-015-0512-5","article-title":"Tumor-induced osteomalacia: an up-to-date review","volume":"17","author":"Hautmann","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0290","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12891-015-0496-3","article-title":"Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors","volume":"16","author":"Sun","year":"2015","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bone.2018.06.011_bb0295","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00467-014-2979-0","article-title":"Tumor-associated FGF-23-induced hypophosphatemic rickets in children: a case report and review of the literature","volume":"30","author":"Burckhardt","year":"2015","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.bone.2018.06.011_bb0300","doi-asserted-by":"crossref","first-page":"189.e1","DOI":"10.1016\/j.wneu.2015.02.030","article-title":"Osteomalacia-inducing tumors of the brain: a case report, review and a hypothesis","volume":"84","author":"Fathalla","year":"2015","journal-title":"World Neurosurg."},{"key":"10.1016\/j.bone.2018.06.011_bb0305","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00198-013-2286-9","article-title":"High bone mineral apparent density in children with X-linked hypophosphatemia","volume":"24","author":"Beck-Nielsen","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0310","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11914-015-0259-y","article-title":"Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis","volume":"13","author":"Goldsweig","year":"2015","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0315","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.bone.2018.06.011_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","article-title":"The expanding family of hypophosphatemic syndromes","volume":"30","author":"Carpenter","year":"2012","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0325","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MOP.0000000000000064","article-title":"Inherited disorders of calcium and phosphate metabolism","volume":"26","author":"Gattineni","year":"2014","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.bone.2018.06.011_bb0330","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11914-014-0223-2","article-title":"Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis","volume":"12","author":"White","year":"2014","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0335","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11154-008-9075-3","article-title":"Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation","volume":"9","author":"Bastepe","year":"2008","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.bone.2018.06.011_bb0340","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1297\/cpe.15.129","article-title":"Molecular bases of diseases characterized by hypophosphatemia and phosphaturia: new understanding","volume":"15","author":"Ozono","year":"2006","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"10.1016\/j.bone.2018.06.011_bb0345","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0004563214521399","article-title":"Phosphate homeostasis and disorders","volume":"51","author":"Manghat","year":"2014","journal-title":"Ann. Clin. Biochem. Ann. Int. J. Biochem. Lab. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0350","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11914-014-0220-5","article-title":"Sclerosing bone dysplasias: leads toward novel osteoporosis treatments","volume":"12","author":"Fijalkowski","year":"2014","journal-title":"Curr. Osteoporos. Rep."},{"issue":"Suppl 1","key":"10.1016\/j.bone.2018.06.011_bb0355","doi-asserted-by":"crossref","first-page":"i119","DOI":"10.1136\/ard.2010.141150","article-title":"Targeting sclerostin as potential treatment of osteoporosis","volume":"70","author":"Papapoulos","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2018.06.011_bb0360","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11914-014-0188-1","article-title":"Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions","volume":"12","author":"Weivoda","year":"2014","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0365","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11914-011-0089-5","article-title":"Sclerostin: therapeutic horizons based upon its actions","volume":"10","author":"Costa","year":"2012","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0370","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cytogfr.2005.02.005","article-title":"SOST\/sclerostin, an osteocyte-derived negative regulator of bone formation","volume":"16","author":"van Bezooijen","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bone.2018.06.011_bb0375","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1759720X13510479","article-title":"Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases","volume":"6","author":"Lewiecki","year":"2014","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.bone.2018.06.011_bb0380","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease\u2014Improving Global Outcomes (KDIGO) controversies conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0385","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00198-011-1781-0","article-title":"Fracture risk assessment in patients with chronic kidney disease","volume":"23","author":"Jamal","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0390","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/joim.12361","article-title":"How to predict and treat increased fracture risk in chronic kidney disease","volume":"278","author":"West","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0395","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrneph.2013.198","article-title":"Evaluating bone quality in patients with chronic kidney disease","volume":"9","author":"Malluche","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bone.2018.06.011_bb0400","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ndt\/gfv081","article-title":"Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications","volume":"30","author":"Morena","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bone.2018.06.011_bb0405","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11154-015-9318-z","article-title":"The PTH-vitamin D-FGF23 axis","volume":"16","author":"Blau","year":"2015","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.bone.2018.06.011_bb0410","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bone.2013.05.004","article-title":"Renal function and bone mineral density in community-dwelling elderly Japanese men: the Fujiwara-kyo osteoporosis risk in men (FORMEN) study","volume":"56","author":"Fujita","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0415","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11255-012-0156-6","article-title":"Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients","volume":"45","author":"Yamashita","year":"2013","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.bone.2018.06.011_bb0420","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2013.02.366","article-title":"Bone alkaline phosphatase in CKD-mineral bone disorder","volume":"62","author":"Sardiwal","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bone.2018.06.011_bb0425","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lfs.2011.11.006","article-title":"Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients","volume":"90","author":"Kobayashi","year":"2012","journal-title":"Life Sci."},{"key":"10.1016\/j.bone.2018.06.011_bb0430","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0435","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.2010121275","article-title":"Discriminants of prevalent fractures in chronic kidney disease","volume":"22","author":"Nickolas","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bone.2018.06.011_bb0440","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000356394","article-title":"Potential for biomarkers of chronic kidney disease-mineral bone disorder to improve patient care","volume":"124","author":"Alderson","year":"2013","journal-title":"Nephron. Clin. Pract."},{"key":"10.1016\/j.bone.2018.06.011_bb0445","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2478\/ams-2013-0026","article-title":"Age and gender predict OPG level and OPG\/sRANKL ratio in maintenance hemodialysis patients","volume":"58","author":"Naumnik","year":"2013","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.bone.2018.06.011_bb0450","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","article-title":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2014a single-center cohort study","volume":"27","author":"Iimori","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bone.2018.06.011_bb0455","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/cen.12070","article-title":"The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis","volume":"78","author":"Yamada","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.bone.2018.06.011_bb0460","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","article-title":"Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis","volume":"67","author":"Sprague","year":"2016","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.bone.2018.06.011_bb0465","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1681\/ASN.2017050584","article-title":"Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy","volume":"29","author":"Salam","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bone.2018.06.011_bb0470","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.bone.2012.02.634","article-title":"Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis","volume":"50","author":"Nakano","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0475","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1440-1797.2011.01443.x","article-title":"Fibroblast growth factor 23 in chronic kidney disease: new insights and clinical implications","volume":"16","author":"Damasiewicz","year":"2011","journal-title":"Nephrology"},{"key":"10.1016\/j.bone.2018.06.011_bb0480","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000353593","article-title":"The role of fibroblast growth factor-23 in cardiorenal syndrome","volume":"123","author":"Kovesdy","year":"2013","journal-title":"Nephron. Clin. Pract."},{"key":"10.1016\/j.bone.2018.06.011_bb0485","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cca.2011.02.009","article-title":"Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies","volume":"412","author":"Smith","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bone.2018.06.011_bb0490","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/jc.2009-1603","article-title":"Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active","volume":"95","author":"Shimada","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0495","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0500","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S8756-3282(98)00193-8","article-title":"Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products","volume":"24","author":"Garnero","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0505","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/484280","article-title":"Bone remodelling markers in rheumatoid arthritis","volume":"2014","author":"Fardellone","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bone.2018.06.011_bb0510","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3899\/jrheum.120397","article-title":"Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis","volume":"40","author":"Szentpetery","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2018.06.011_bb0515","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-013-2334-5","article-title":"Can bone loss in rheumatoid arthritis be prevented?","volume":"24","author":"Vis","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0520","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3899\/jrheum.121392","article-title":"Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritis","volume":"40","author":"Krabben","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2018.06.011_bb0525","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/1756-185X.12115","article-title":"Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients","volume":"17","author":"Iwadate","year":"2014","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.bone.2018.06.011_bb0530","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jbspin.2012.08.004","article-title":"Common bone turnover markers in rheumatoid arthritis and ankylosing spondylitis: a literature review","volume":"80","author":"Coiffier","year":"2013","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.bone.2018.06.011_bb0535","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/ar3280","article-title":"Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities","volume":"13","author":"M A","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bone.2018.06.011_bb0540","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11914-013-0172-1","article-title":"Osteoporosis and osteoarthritis, rheumatoid arthritis and spondylarthropathies","volume":"11","author":"Clayton","year":"2013","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0545","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/537324","article-title":"Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients?","volume":"2014","author":"D\u00e9nari\u00e9","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bone.2018.06.011_bb0550","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1007\/s00198-014-2819-x","article-title":"Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients","volume":"25","author":"Ebina","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0555","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/ard.2009.121764","article-title":"Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11\u202fyears in rheumatoid arthritis","volume":"69","author":"van Tuyl","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2018.06.011_bb0560","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/rheumatology\/kes369","article-title":"Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP\u2014a possible mechanism for specific inhibition of radiological destruction","volume":"52","author":"Engvall","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2018.06.011_bb0565","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis","volume":"65","author":"Vis","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2018.06.011_bb0570","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.bone.2013.05.018","article-title":"OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the women's health initiative observational study","volume":"56","author":"Lacroix","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0575","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.maturitas.2013.01.005","article-title":"Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor \u03baB ligand in the diagnosis of osteoporosis","volume":"74","author":"Piatek","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2018.06.011_bb0580","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s10354-010-0818-x","article-title":"Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?","volume":"160","author":"Wagner","year":"2010","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.bone.2018.06.011_bb0585","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jbo.2012.12.004","article-title":"Incidence and consequences of bone metastases in lung cancer patients","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bone.2018.06.011_bb0590","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","article-title":"Metastatic prostate cancer and the bone: significance and therapeutic options","volume":"68","author":"Gartrell","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bone.2018.06.011_bb0595","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10517-014-2663-1","article-title":"Biochemical markers of bone metabolism in breast cancer","volume":"157","author":"Lyubimova","year":"2014","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0600","first-page":"425","article-title":"Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis","volume":"1846","author":"Jung","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bone.2018.06.011_bb0605","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jbo.2013.01.002","article-title":"Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features \u2014 an exploratory analysis of placebo-controlled trials","volume":"2","author":"Coleman","year":"2013","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bone.2018.06.011_bb0610","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2018.06.011_bb0615","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.trsl.2010.01.002","article-title":"Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid","volume":"155","author":"Mountzios","year":"2010","journal-title":"Transl. Res."},{"key":"10.1016\/j.bone.2018.06.011_bb0620","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","article-title":"Five years of anti-resorptive activity after a single dose of zoledronate\u2014results from a randomized double-blind placebo-controlled trial","volume":"50","author":"Grey","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0625","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cca.2013.09.011","article-title":"Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients","volume":"426","author":"Tang","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bone.2018.06.011_bb0630","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10147-011-0266-7","article-title":"The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer","volume":"17","author":"Bayrak","year":"2012","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bone.2018.06.011_bb0635","first-page":"2593","article-title":"Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type i collagen as markers of bone metastases in patients with non-small cell lung cancer","volume":"33","author":"Lumachi","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bone.2018.06.011_bb0640","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cllc.2011.03.032","article-title":"Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data","volume":"12","author":"Mountzios","year":"2011","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bone.2018.06.011_bb0645","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2010.09.038","article-title":"Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients","volume":"412","author":"Yao","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bone.2018.06.011_bb0650","first-page":"43","article-title":"ICTP in bone metastases of lung cancer","volume":"35","author":"Franjevi\u0107","year":"2011","journal-title":"Coll. Antropol."},{"key":"10.1016\/j.bone.2018.06.011_bb0655","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.cllc.2012.11.006","article-title":"Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer","volume":"14","author":"Tamiya","year":"2013","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bone.2018.06.011_bb0660","first-page":"3879","article-title":"Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results","volume":"31","author":"Lumachi","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bone.2018.06.011_bb0665","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.canep.2011.02.001","article-title":"Biochemical-markers for the diagnosis of bone metastasis: a clinical review","volume":"36","author":"Huang","year":"2012","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.bone.2018.06.011_bb0670","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1442-2042.2011.02914.x","article-title":"Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade","volume":"19","author":"Kamiya","year":"2012","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.bone.2018.06.011_bb0675","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cca.2014.06.025","article-title":"Serum crosslinked-N-terminal telopeptide of type I collagen (NTx) has prognostic implications for patients with initial prostate carcinoma (PCa): a pilot study","volume":"436","author":"Jablonka","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bone.2018.06.011_bb0680","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2011.11.009","article-title":"Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer","volume":"61","author":"Armstrong","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bone.2018.06.011_bb0685","doi-asserted-by":"crossref","first-page":"R216","DOI":"10.1186\/ar4055","article-title":"Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?","volume":"14","author":"Saad","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bone.2018.06.011_bb0690","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.urolonc.2010.07.002","article-title":"Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy","volume":"30","author":"Sonpavde","year":"2012","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.bone.2018.06.011_bb0700","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju013","article-title":"Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421","volume":"106","author":"Lara","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bone.2018.06.011_bb0705","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/bjc.2012.436","article-title":"Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials","volume":"107","author":"Som","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bone.2018.06.011_bb0710","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/annonc\/mdq037","article-title":"Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer","volume":"21","author":"Rajpar","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2018.06.011_bb0715","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1464-410X.2011.10192.x","article-title":"Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis","volume":"109","author":"Izumi","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0720","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-410X.2012.11759.x","article-title":"Serum receptor activator of nuclear factor \u03bab ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy","volume":"113","author":"Todenh\u00f6fer","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0725","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cca.2010.06.027","article-title":"Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis","volume":"411","author":"Chao","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bone.2018.06.011_bb0730","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bone.2014.07.036","article-title":"Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study)","volume":"68","author":"Barnadas","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0735","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-015-0390-5","article-title":"Osteoprotegerin in breast cancer: beyond bone remodeling","volume":"14","author":"Weichhaus","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bone.2018.06.011_bb0740","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2010.31.5069","article-title":"Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14","volume":"29","author":"Lipton","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2018.06.011_bb0745","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3892\/or.2013.2409","article-title":"Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer","volume":"30","author":"Aktas","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0750","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11899-012-0135-0","article-title":"Prevention and treatment of myeloma bone disease","volume":"7","author":"Terpos","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"1","key":"10.1016\/j.bone.2018.06.011_bb0755","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.13928","article-title":"Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma","volume":"173","author":"Ting","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2018.06.011_bb0760","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12032-010-9432-4","article-title":"Osteolytic lesions marker in multiple myeloma","volume":"28","author":"Djunic","year":"2011","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bone.2018.06.011_bb0765","first-page":"S574","article-title":"Prognostic and medical relevance of bone turnover markers for multiple myeloma patients: an evidence based approach for clinical laboratory","volume":"53","author":"Pecoraro","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.bone.2018.06.011_bb0770","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.clinbiochem.2009.12.018","article-title":"Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma","volume":"43","author":"Kowalska","year":"2010","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bone.2018.06.011_bb0775","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bone.2018.06.011_bb0780","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1158\/1078-0432.CCR-14-0434","article-title":"Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy","volume":"20","author":"Patel","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2018.06.011_bb0785","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.nut.2015.06.012","article-title":"Association between basal metabolic function and bone metabolism in postmenopausal women with type 2 diabetes","volume":"31","author":"Ogata","year":"2015","journal-title":"Nutrition"},{"key":"10.1016\/j.bone.2018.06.011_bb0790","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2015.11.004","article-title":"Differences in biochemical bone markers by diabetes type and the impact of glucose","volume":"83","author":"Starup-Linde","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0795","doi-asserted-by":"crossref","DOI":"10.1210\/er.2012-1042","article-title":"The impact of diabetes treatments on bone health in patients with type 2 diabetes mellitus","volume":"36","author":"Gilbert","year":"2015","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2018.06.011_bb0800","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12020-015-0535-8","article-title":"Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus","volume":"50","author":"Rubin","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.bone.2018.06.011_bb0805","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1210\/jc.2011-2958","article-title":"Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes","volume":"97","author":"Gennari","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0810","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bone.2018.04.004","article-title":"Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes","volume":"112","author":"Stage","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0815","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1530\/EJE-15-0820","article-title":"Mechanisms in endocrinology: mechanisms and evaluation of bone fragility in type 1 diabetes mellitus","volume":"174","author":"Hough","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2018.06.011_bb0820","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph13060544","article-title":"BMI and BMD: the potential interplay between obesity and bone fragility","volume":"13","author":"Palermo","year":"2016","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.bone.2018.06.011_bb0825","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1507\/endocrj.EJ15-0129","article-title":"Insights into bone fragility in diabetes: the crucial role of bone quality on skeletal strength","volume":"62","author":"Yamamoto","year":"2015","journal-title":"Endocr. J."},{"key":"10.1016\/j.bone.2018.06.011_bb0830","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12018-015-9178-9","article-title":"Diabetes and bone: still a lot to learn","volume":"13","author":"Chaiban","year":"2015","journal-title":"Clin. Rev. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0835","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/jc.2014-3019","article-title":"Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men","volume":"100","author":"Yeap","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0840","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11914-015-0260-5","article-title":"Diabetes, diabetic complications, and fracture risk","volume":"13","author":"Oei","year":"2015","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2018.06.011_bb0845","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00592-015-0792-2","article-title":"Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes","volume":"52","author":"Li","year":"2015","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.bone.2018.06.011_bb0850","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bone.2015.02.019","article-title":"Biochemical bone turnover markers in diabetes mellitus \u2014 a systematic review","volume":"82","author":"Starup-Linde","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0855","first-page":"490","article-title":"New insights on diabetes and bone metabolism","volume":"37","author":"Moreira","year":"2015","journal-title":"J. Bras. Nefrol'org\u00e3o Soc. Bras. atino-Am. Nefrol."},{"key":"10.1016\/j.bone.2018.06.011_bb0860","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00198-011-1595-0","article-title":"Bone structure and turnover in type 2 diabetes mellitus","volume":"23","author":"Shu","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0865","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/564934","article-title":"Osteoprotegerin in cardiometabolic disorders","volume":"2015","author":"P\u00e9rez de Ciriza","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.bone.2018.06.011_bb0870","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.diabres.2013.03.007","article-title":"The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients","volume":"100","author":"Chen","year":"2013","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.bone.2018.06.011_bb0875","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bone.2015.04.026","article-title":"Effects of diabetes drugs on the skeleton","volume":"82","author":"Meier","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0880","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1210\/jc.2013-2472","article-title":"Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study","volume":"98","author":"D\u00edaz-L\u00f3pez","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0885","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10654-015-0058-x","article-title":"Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence","volume":"30","author":"Kunutsor","year":"2015","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.bone.2018.06.011_bb0890","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.bone.2010.12.020","article-title":"Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes","volume":"48","author":"Kanazawa","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.06.011_bb0895","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-3978","article-title":"Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial","volume":"99","author":"Rolighed","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0900","first-page":"640","article-title":"The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy","volume":"35","author":"Alonso","year":"2012","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bone.2018.06.011_bb0905","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2009-2384","article-title":"Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis","volume":"95","author":"Sankaran","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.06.011_bb0910","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00198-011-1806-8","article-title":"Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study","volume":"23","author":"Ardawi","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0915","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.surg.2012.08.015","article-title":"Changes in bone mineral density after surgical intervention for primary hyperparathyroidism","volume":"152","author":"Dy","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.bone.2018.06.011_bb0920","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1055\/s-0033-1349842","article-title":"Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate","volume":"45","author":"Szymczak","year":"2013","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.bone.2018.06.011_bb0925","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10354-012-0125-9","article-title":"Bone turnover in hyperparathyroidism","volume":"163","author":"Kerschan-Schindl","year":"2013","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.bone.2018.06.011_bb0930","first-page":"S310","article-title":"The relationship between osteoprotegerin, RANKL and bone turnover markers among postmenopausal women with and without osteoporosis: a cross-sectional study","volume":"23","author":"Ardawi","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.06.011_bb0935","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1530\/EJE-11-0589","article-title":"Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism","volume":"165","author":"Bollerslev","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2018.06.011_bb0940","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bmj.e1013","article-title":"Diagnosis and management of primary hyperparathyroidism","volume":"344","author":"Pallan","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2018.06.011_bb0945","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-12-0528","article-title":"Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature","volume":"168","author":"Witteveen","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2018.06.011_bb0950","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40618-015-0261-3","article-title":"Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism","volume":"38","author":"Marcocci","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bone.2018.06.011_bb0955","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00223-011-9489-x","article-title":"Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism","volume":"89","author":"Rossini","year":"2011","journal-title":"Calcif. Tissue Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218302436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218302436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:43:40Z","timestamp":1757612620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328218302436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":189,"alternative-id":["S8756328218302436"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2018.06.011","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical utility of bone markers in various diseases","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2018.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}